What elements should be included in an EHR template for alcohol‑use counseling in adult male patients (≥18 years), covering demographics, AUDIT (Alcohol Use Disorders Identification Test) screening and score, drinking pattern, risk assessment, co‑existing conditions, brief motivational‑interviewing intervention, pharmacologic options (naltrexone, acamprosate, disulfiram), non‑pharmacologic referrals, and follow‑up plan?

EHR Template for Alcohol Use Counseling in Adult Males

An effective EHR template for alcohol counseling in adult males should include structured fields for AUDIT-C screening (the preferred brief tool), drinking pattern documentation, brief behavioral counseling intervention notes, and pharmacotherapy options with naltrexone as first-line medication. 1

Essential Template Components

Demographics & Basic Information

• Age (≥18 years)
• Sex (male)
• Date of screening
• Chief complaint/reason for visit

Screening Section

Primary Screening Tool: AUDIT-C (3 questions, 1-2 minutes)

The AUDIT-C is the preferred screening instrument for males, requiring documentation of 1:

• Question 1: How often do you have a drink containing alcohol? (Never/Monthly or less/2-4 times per month/2-3 times per week/4+ times per week)
• Question 2: How many standard drinks do you have on a typical day when drinking? (1-2/3-4/5-6/7-9/10+)
• Question 3: How often do you have 6 or more drinks on one occasion? (Never/Less than monthly/Monthly/Weekly/Daily or almost daily)

AUDIT-C Score: [Auto-calculate: 0-12 points]

• Positive screen for males: ≥5 points 1
• Possible dependence: ≥10 points 2

Alternative: Single-question screen: "How many times in the past year have you had 5 or more drinks in a day?" (Any positive response = risky drinking) 1

Drinking Pattern Assessment

Document specific consumption patterns 1:

• Daily consumption: Number of drinks per day
• Weekly consumption: Total drinks per week
• Binge episodes: Frequency of ≥5 drinks per occasion for males
• Risky use definition for males: >4 drinks/day OR >14 drinks/week 1
• Duration of current pattern: Years/months
• Previous quit attempts: Number and duration

Risk Stratification

Classification 1:

• Low risk: Below thresholds
• Risky/hazardous use: Exceeds daily/weekly limits
• Harmful use: Physical/mental health damage present
• Alcohol dependence: Cravings, withdrawal, tolerance, loss of control

Co-existing Conditions Assessment

Document presence of 3, 4:

• Psychiatric comorbidities: Depression (screen for suicidality), anxiety, psychotic disorders, PTSD
• Medical complications: Liver disease (AST, ALT, GGT levels), pancreatitis, hypertension, cardiomyopathy
• Laboratory biomarkers:
  • AST, ALT, GGT (elevated with higher AUDIT scores) 3
  • MCV (mean corpuscular volume - elevated with chronic use) 3
  • Total cholesterol 3
• Social consequences: Legal problems, relationship issues, work/school failures
• Contraindications to specific medications: Severe renal impairment (contraindication to acamprosate), opioid use (contraindication to naltrexone)

Brief Behavioral Counseling Intervention

Document intervention type delivered 1:

Brief multicontact counseling (6-15 minutes per contact, multiple sessions) has the best evidence 1. Template should include:

• Feedback: Personalized information on drinking patterns vs. recommended limits
• Responsibility: Emphasize patient choice in changing behavior
• Advice: Clear recommendation to reduce drinking to safe limits (≤4 drinks/day, ≤14 drinks/week for males) 1
• Menu of options: Discuss strategies (drinking diary, avoiding triggers, alternating with non-alcoholic drinks)
• Empathy: Non-judgmental, supportive approach
• Self-efficacy: Reinforce confidence in ability to change

Cognitive-behavioral components documented 5:

• Action plan created: Yes/No [specify plan]
• Drinking diary provided: Yes/No
• Stress management discussed: Yes/No
• Problem-solving strategies: Yes/No

Patient response 6:

• Willingness to change: Yes/No/Contemplating
• Perceived problem with drinking: Yes/No
• Comfort level with discussion: Comfortable/Uncomfortable

Pharmacotherapy Options

For patients with moderate-severe AUD or those seeking medication support 4, 7:

Goal: Reduction of Alcohol Consumption

First-line 7, 8:

• Naltrexone: 50 mg PO daily (reduces return to any drinking by 5%, binge drinking by 10%) 4
  • Contraindications: Current opioid use, acute hepatitis, liver failure
  • Mechanism: Opioid receptor antagonist, reduces rewarding effects of alcohol
• Nalmefene: As-needed dosing option 7

Second-line 7:

• Baclofen: When first-line partially effective or ineffective

Goal: Maintenance of Abstinence

First-line 7, 8:

• Acamprosate: 666 mg PO three times daily 9, 7
  • Contraindications: Severe renal impairment (CrCl <30 mL/min) 9
  • Dose adjustment: Moderate renal impairment (CrCl 30-50): 333 mg TID 9
  • Mechanism: Modulates glutamate neurotransmission

Second-line options 7:

• Disulfiram: 250-500 mg PO daily (for highly motivated patients accepting aversive therapy)
• Naltrexone: Alternative for abstinence maintenance
• Baclofen: For patients with liver disease
• Sodium oxybate: For severe AUD

Combined pharmacotherapy: Consider in highly adherent patients with inadequate response to monotherapy 5, 7

Medication prescribed: [Dropdown: None/Naltrexone/Acamprosate/Disulfiram/Other] Dose and frequency: [Free text] Patient education provided: Yes/No Monitoring plan: [Specify labs, frequency]

Non-pharmacologic Referrals

Evidence-based therapy referral 5:

• Cognitive Behavioral Therapy (CBT): Combined with pharmacotherapy shows benefit over usual care 5
• Motivational Enhancement Therapy: Equivalent efficacy to CBT 5
• Contingency Management: Evidence-based alternative 5
• Mutual support groups: AA, SMART Recovery
• Intensive outpatient program: For severe AUD
• Addiction psychiatry/medicine consultation: For complex cases

Referral made: Yes/No [specify type]

Follow-up Plan

Structured follow-up is essential 1:

• Next appointment: [Date, 2-4 weeks recommended initially]
• Follow-up method: In-person/Telehealth/Phone
• Monitoring parameters:
  • Self-reported drinking (days abstinent, drinks per drinking day)
  • Adherence to medication (if prescribed)
  • Side effects assessment
  • Laboratory monitoring (if indicated): AST, ALT, GGT at baseline and follow-up
  • Psychiatric symptoms (depression, suicidality) 9
• Reassessment: Repeat AUDIT-C at follow-up visits
• Treatment adjustment plan: Document criteria for escalating or changing therapy

Clinical Alerts/Flags

Automatic alerts for 9:

• Suicidality screening positive (acamprosate black box warning for depression/suicidality)
• Severe renal impairment documented (contraindication to acamprosate)
• Active opioid use (contraindication to naltrexone)
• Acute alcohol withdrawal symptoms (requires medical management, not just counseling)

Key Implementation Notes

The USPSTF gives a Grade B recommendation for screening all adults ≥18 years and providing brief behavioral counseling for risky/hazardous drinking 1. This template operationalizes that recommendation with structured documentation supporting both screening and intervention.

Common pitfall: Very brief interventions (≤5 minutes) have limited effectiveness 1. Ensure adequate time allocation for meaningful counseling (6-15 minutes minimum).

Medication underutilization: Despite evidence, <9% of appropriate patients receive pharmacotherapy 4. This template prompts consideration of medications as first-line treatment alongside counseling, not as a last resort.

Combined approach superiority: Pharmacotherapy plus evidence-based behavioral therapy (CBT or equivalent) outperforms usual care plus medication 5. The template should facilitate both components, not just counseling alone.